Soleno Therapeutics (SLNO) Falls Hard on Patient Death

We recently published 10 Stocks Melt Down in Hours. Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the worst performers on Wednesday.

Soleno Therapeutics dropped for a second day on Wednesday, shedding 14.52 percent to end at $60.01 apiece as investors turned cautious following the death of a patient who had been taking its Vykat XR drug.

In a regulatory filing, Soleno Therapeutics, Inc. (NASDAQ:SLNO) said it was made aware of a report by the Food and Drug Administration (FDA) that a 17-year-old patient succumbed, but stood firm that the death was not related to the intake of the Vykat XR drug.

“The treating physician has reported the case as not related to treatment with Vykat XR, and Soleno’s assessment is the same. This patient was a 17-year-old male with a history of co-morbidities, including lymphedema, superficial thrombophlebitis (treated and followed by a vascular surgery team), and obesity (326 lbs.) who died from an apparent pulmonary embolus,” Soleno Therapeutics, Inc. (NASDAQ:SLNO) said.

“Vykat XR has a proven safety and efficacy profile and was approved by the FDA following a rigorous clinical program. Like any medication, Vykat XR should be administered in accordance with its FDA-approved label, which describes anticipated side effects. Soleno Therapeutics is committed to reporting all adverse events experienced by individuals who have taken Vykat XR in accordance with applicable law,” it added.

While we acknowledge the potential of SLNO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.